Shares of Omeros Corporation (NASDAQ:OMER) saw unusually-high trading volume on Thursday . Approximately 1,116,012 shares traded hands during trading, an increase of 200% from the previous session’s volume of 371,756 shares.The stock last traded at $11.54 and had previously closed at $12.87.

OMER has been the topic of several recent analyst reports. Maxim Group restated a “buy” rating on shares of Omeros Corporation in a research report on Wednesday, April 20th. Wedbush restated an “outperform” rating and set a $62.00 price objective on shares of Omeros Corporation in a research report on Tuesday, May 10th. Cantor Fitzgerald initiated coverage on shares of Omeros Corporation in a research report on Thursday, June 2nd. They set a “buy” rating and a $21.00 price objective on the stock. WBB Securities restated a “buy” rating and set a $75.00 price objective on shares of Omeros Corporation in a research report on Tuesday, June 14th. Finally, FBR & Co restated an “outperform” rating and set a $38.00 price objective on shares of Omeros Corporation in a research report on Wednesday, June 29th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $36.13.

The company’s market cap is $452.26 million. The stock’s 50 day moving average price is $11.43 and its 200 day moving average price is $12.21.

Omeros Corporation (NASDAQ:OMER) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.18. The company had revenue of $10 million for the quarter, compared to analysts’ expectations of $9.80 million. The firm’s revenue for the quarter was up 212.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.44) EPS. Analysts predict that Omeros Corporation will post ($1.70) earnings per share for the current year.

In other news, VP Marcia S. Kelbon sold 15,900 shares of the company’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $11.50, for a total value of $182,850.00. Following the sale, the vice president now directly owns 179,497 shares of the company’s stock, valued at approximately $2,064,215.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A hedge fund recently raised its stake in Omeros Corporation stock. Nationwide Fund Advisors raised its stake in shares of Omeros Corporation (NASDAQ:OMER) by 183.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,700 shares of the biopharmaceutical company’s stock after buying an additional 45,145 shares during the period. Nationwide Fund Advisors owned approximately 0.18% of Omeros Corporation worth $1,096,000 at the end of the most recent quarter.

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.